Previous 10 | Next 10 |
home / stock / orxoy / orxoy news
The following slide deck was published by Orexo AB (publ) in conjunction with this Read more ...
UPPSALA, Sweden , Nov. 8, 2019 /PRNewswire/ -- Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the company will present at the Jefferies Healthcare Conference on Wednesday, November 20 , 2019, ...
Orexo AB ( OTCQX:ORXOY ): Q3 GAAP EPS of SEK3.16. More news on: Orexo AB (publ), OREXO AB ORD, Earnings news and commentary, Healthcare stocks news, , Read more ...
Strong financials paving the way for broadening the business UPPSALA, Sweden , Oct. 24, 2019 Q3 2019 highlights Total net revenues of SEK 231.2 million (216.6), up 6.7 percent Zubsolv® US net revenues of SEK 182.7 million (165.4), up 10.4 percent in SEK and 3.0 percent i...
UPPSALA, Sweden , Oct. 14, 2019 /PRNewswire/ -- Prior to the Annual General Meeting (AGM) in 2020, Orexo has appointed a Nomination Committee which represents approximately 44 percent of the number of votes in the company as of September 30, 2019 . The Nomination Committee, comprises: ...
UPPSALA, Sweden , Aug. 20, 2019 /PRNewswire/ -- Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces it has entered into an exclusive agreement with GAIA AG (GAIA), a global leader in digital therapeutics that succe...
NEW YORK , July 15, 2019 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the July 11 th life sciences conference are now available for on-demand viewing at VirtualInvestorConferences.com....
Improving all fundamentals UPPSALA, Sweden , July 11, 2019 /PRNewswire/ -- Q2 2019 highlights Total net revenues of SEK 201.2 million (199.7), up 0.8 percent and 19.1 percent when excluding ex-US milestone payment of SEK 30.8 million in Q2 2018 Zubsolv® US net ...
Orexo AB ( OTCQX:ORXOY ) has signed an agreement granting Mundipharma Pty Limited the exclusive rights to commercialize Orexo's Zubsolv, for the treatment of opioid dependence, in Australia and New Zealand. More news on: Orexo AB (publ), Healthcare stocks news, Read more ...
UPPSALA, Sweden , July 10, 2019 /PRNewswire/ -- Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces the company has signed an agreement granting Mundipharma Pty Limited (Mundipharma Australia) the exclusive rights t...
News, Short Squeeze, Breakout and More Instantly...
Orexo Q2 2024 Interim Report PR Newswire UPPSALA, Sweden , July 17, 2024 /PRNewswire/ -- Making progress, while the OX124 review time extended Q2 2024 highlights Total net revenues of SEK 154.0 m (157.7) EBITDA of SEK 5.0 m (5.6)...
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose PR Newswire UPPSALA, Sweden , July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received...
Orexo AB´s sustainability work ranked among top 5% by EcoVadis PR Newswire UPPSALA, Sweden , July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the...